Why Big Pharma is partnering with startups as it becomes more data-driven
Pfizer re-ups CytoReason collab applying AI disease models to drug development
Merck KGaA taps CytoReason’s machine learning platform to profile immuno-oncology drug
Israel’s CytoReason introduces AI clinical drug development platform to Japan’s pharma market
An Immune System “GPS” Uncovers Pathways to Treat Diseases
The secret Israeli sauce in Pfizer’s new drug mix
AI-Powered Drug Development in a Post-COVID World
When can computer models replace animal trials?
Israeli AI to help Pfizer develop its next drugs
New Startup Helps Pfizer Create More Effective, Targeted Drugs For Patients
